444 related articles for article (PubMed ID: 12461063)
1. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
2. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
Cancer; 2003 Jun; 99(3):172-9. PubMed ID: 12811858
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and Functional Characterization of Ductal Carcinoma In Situ-Associated Myoepithelial Cells.
Rohilla M; Bal A; Singh G; Joshi K
Clin Breast Cancer; 2015 Oct; 15(5):335-42. PubMed ID: 25700939
[TBL] [Abstract][Full Text] [Related]
5. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
[TBL] [Abstract][Full Text] [Related]
6. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
7. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
Dabbs DJ; Chivukula M; Carter G; Bhargava R
Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
[TBL] [Abstract][Full Text] [Related]
8. Availability of immunocytochemistry using cocktail antibody targeting p63/cytokeratin14 for the differential diagnosis of fibroadenoma and ductal carcinoma in situ in fine needle aspiration cytology of the breast.
Maeda I; Oana Y; Tsugawa K; Takagi M
Cytopathology; 2017 Oct; 28(5):378-384. PubMed ID: 28685877
[TBL] [Abstract][Full Text] [Related]
9. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.
Barbareschi M; Pecciarini L; Cangi MG; Macrì E; Rizzo A; Viale G; Doglioni C
Am J Surg Pathol; 2001 Aug; 25(8):1054-60. PubMed ID: 11474290
[TBL] [Abstract][Full Text] [Related]
10. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?
Masood S; Loya A; Khalbuss W
Diagn Cytopathol; 2003 Jun; 28(6):329-34. PubMed ID: 12768640
[TBL] [Abstract][Full Text] [Related]
11. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast?
Ribeiro-Silva A; Zamzelli Ramalho LN; Garcia SB; Zucoloto S
Pathol Oncol Res; 2003; 9(1):20-3. PubMed ID: 12704442
[TBL] [Abstract][Full Text] [Related]
12. P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma.
Shamloula MM; El-Shorbagy SH; Saied EM
J Egypt Natl Canc Inst; 2007 Sep; 19(3):202-10. PubMed ID: 19190693
[TBL] [Abstract][Full Text] [Related]
13. The relationship between p63 and p53 expression in normal and neoplastic breast tissue.
Ribeiro-Silva A; Zambelli Ramalho LN; Britto Garcia S; Zucoloto S
Arch Pathol Lab Med; 2003 Mar; 127(3):336-40. PubMed ID: 12653579
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
15. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
16. Immunocytochemical analysis of p63 and 34βE12 in fine needle aspiration cytology specimens for breast lesions: a potentially useful discriminatory marker between intraductal papilloma and ductal carcinoma in situ.
Hoshikawa S; Sano T; Hirato J; Oyama T; Fukuda T
Cytopathology; 2016 Apr; 27(2):108-14. PubMed ID: 25810244
[TBL] [Abstract][Full Text] [Related]
17. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F
J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900
[TBL] [Abstract][Full Text] [Related]
18. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
19. Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.
Sailer V; Lüders C; Kuhn W; Pelzer V; Kristiansen G
Virchows Arch; 2015 Jul; 467(1):67-70. PubMed ID: 25850754
[TBL] [Abstract][Full Text] [Related]
20. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.
Umekita Y; Yoshida H
Histopathology; 2003 Jun; 42(6):541-5. PubMed ID: 12786889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]